MedPath

AiViva Biopharma, Inc.

AiViva Biopharma, Inc. logo
🇺🇸United States
Ownership
Private
Established
2016-01-01
Employees
11
Market Cap
-
Website
http://www.aiviva.com

Clinical Trials

6

Active:1
Completed:4

Trial Phases

1 Phases

Phase 1:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (100.0%)

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

Phase 1
Active, not recruiting
Conditions
Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Macular Edema
Interventions
First Posted Date
2023-01-26
Last Posted Date
2025-03-06
Lead Sponsor
AiViva BioPharma, Inc.
Target Recruit Count
19
Registration Number
NCT05698329
Locations
🇺🇸

Retina-Vitreous Associates, Beverly Hills, California, United States

🇺🇸

Orange County Retina, Santa Ana, California, United States

🇺🇸

Verum Research, Eugene, Oregon, United States

and more 3 locations

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Phase 1
Completed
Conditions
Keloid
Incision
Scar
Excision Margin
Interventions
First Posted Date
2021-04-01
Last Posted Date
2024-12-27
Lead Sponsor
AiViva BioPharma, Inc.
Target Recruit Count
25
Registration Number
NCT04827875
Locations
🇺🇸

Skin Research Institute, Coral Gables, Florida, United States

🇺🇸

DermResearch DRI, Austin, Texas, United States

🇺🇸

J&S Studies, College Station, Texas, United States

and more 1 locations

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

Phase 1
Completed
Conditions
Superficial Basal Cell Carcinoma
Nodular Basal Cell Carcinoma
Nonmelanoma Skin Cancers
Interventions
Drug: AIV001 suspension
First Posted Date
2020-07-14
Last Posted Date
2025-03-25
Lead Sponsor
AiViva BioPharma, Inc.
Target Recruit Count
26
Registration Number
NCT04470726
Locations
🇺🇸

Skin Surgery Medical Group, San Diego, California, United States

🇺🇸

California Dermatology & Clinical Research Institute, Encinitas, California, United States

🇺🇸

Island Dermatology, Newport Beach, California, United States

and more 1 locations

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

Phase 1
Completed
Conditions
Neovascular Age-related Macular Degeneration
Interventions
First Posted Date
2020-06-09
Last Posted Date
2024-12-27
Lead Sponsor
AiViva BioPharma, Inc.
Target Recruit Count
3
Registration Number
NCT04422899
Locations
🇺🇸

Salehi Retina Institute, Huntington Beach, California, United States

🇺🇸

Retina Research Institute of Texas, Abilene, Texas, United States

A Safety and Efficacy Study to Evaluate Rosacea

Phase 1
Withdrawn
Conditions
Papulopustular Rosacea
Interventions
Drug: Vehicle
First Posted Date
2019-03-21
Last Posted Date
2024-12-17
Lead Sponsor
AiViva BioPharma, Inc.
Registration Number
NCT03883945
Locations
🇺🇸

Cosmetic Laser Dermatology, San Diego, California, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.